2021 Request for Applications

Coalition to Cure Calpain 3 requests applications for research and translational projects related to calpain 3 and limb-girdle muscular dystrophy type 2A (LGMD2A, also called LGMDR1 Calpain 3-related). The goal of the RFA is to enable the development of therapeutic approaches for this disease. This opportunity is open to investigators from both US and non-US based academic and biopharmaceutical organizations. Letters of Intent are due by September 1, 2021, with full applications due by November 1, 2021.

The RFA can be found here.